| Literature DB >> 33179025 |
Elise M A Slob1,2, Bronwyn K Brew3,4, Susanne J H Vijverberg1,2, Talitha Dijs1,5, Catharina E M van Beijsterveldt6, Gerard H Koppelman7,8, Meike Bartels6, Conor V Dolan6, Henrik Larsson3,9, Sebastian Lundström10, Paul Lichtenstein3, Tong Gong3, Anke H Maitland-van der Zee1,2, Aletta D Kraneveld11,12, Catarina Almqvist3,13, Dorret I Boomsma6.
Abstract
BACKGROUND: Development of the gut-brain axis in early life may be disturbed by antibiotic use. It has been hypothesized that this disturbance may contribute to development of neurodevelopmental disorders, including autism spectrum disorder and attention-deficit hyperactivity disorder. We aimed to assess the association between antibiotic use in early life and the risk of developing attention-deficit hyperactivity disorder or autism spectrum disorder, while controlling for shared genetic and environmental factors in a discordant twin design.Entities:
Keywords: ADHD; ASD; antibiotics; children; discordant twin design; early life; gut-brain axis
Year: 2021 PMID: 33179025 PMCID: PMC8248483 DOI: 10.1093/ije/dyaa168
Source DB: PubMed Journal: Int J Epidemiol ISSN: 0300-5771 Impact factor: 7.196
Summary characteristics of Dutch (NTR) and Swedish (CATSS) twin cohorts and subgroups with ASD and ADHD
| All individuals
NTR | ADHD | All
individuals | ADHD | All individuals
NTR | ASD | All
individuals | ASD | |
|---|---|---|---|---|---|---|---|---|
| Gender | ||||||||
| Male | 10 549 (47.9%) | 1611 (52.8%) | 3978 (50.1%) | 700 (65.4%) | 11 860 (48.8%) | 1516 (50.4%) | 3978 (50.1%) | 243 (69.4%) |
| Delivery mode | ||||||||
| Caesarean section | 6272 (30.5%) | 922 (32.0%) | 3265 (52.1%) | 447 (52.8%) | 6528 (26.9%) | 852 (28.3%) | 3265 (52.1%) | 140 (54.7%) |
| Gestational age | ||||||||
| <37 wk | 1727 (56.5%) | 13 052 (59.2%) | 4283 (53.9%) | 607 (56.7%) | 9834 (40.4%) | 1366 (45.4%) | 4283 (53.9%) | 214 (61.1%) |
| Birthweight (g) | 2492 (720) | 2452 (760) | 2670 (720) | 2635 (828) | 2493 (721) | 2410 (790) | 2670 (720) | 2635 (817) |
| Breastfeeding | NA | NA | NA | NA | ||||
| None | 9084 (41.4%) | 1223 (40.1%) | 10 267 (42.4%) | 1214 (40.5%) | ||||
| <2 wk | 2210 (10.1%) | 321 (10.5%) | 2377 (9.8%) | 341 (11.4%) | ||||
| 2-6 wk | 3381 (15.4%) | 512 (16.8%) | 3696 (15.3%) | 467 (15.6%) | ||||
| 6 wk–3 mths | 2895 (13.2%) | 427 (14.0%) | 3125 (12.9%) | 383 (12.8%) | ||||
| 3-6 mths | 2223 (10.1%) | 284 (9.3%) | 2434 (10.1%) | 297 (9.9%) | ||||
| > 6mths | 2171 (9.9%) | 280 (9.1%) | 2300 (9.5%) | 298 (9.9%) | ||||
| Educational attainment, mother | ||||||||
| ≤9 years | 877 (4.0%) | 190 (6.3%) | 166 (2.3%) | 42 (4.5%) | 1109 (4.6%) | 159 (5.3%) | 166 (2.3%) | 17 (5.5%) |
| 10-12 years | 5513 (25.4%) | 818 (27.2%) | 1934 (27.2%) | 347 (37.2%) | 6468 (27.0%) | 826 (27.7%) | 1934 (27.2%) | 118 (38.2%) |
| <2 years tertiary | 9175 (42.2%) | 1303 (43.4%) | 962 (13.6%) | 164 (17.6%) | 9943 (41.5%) | 1268 (42.6%) | 962 (13.6%) | 51 (16.5%) |
| ≥2 years tertiary | 6167 (28.4%) | 691 (23.0%) | 4036 (56.9%) | 381 (40.8%) | 6436 (26.9%) | 727 (24.4%) | 4036 (56.9%) | 123 (39.8%) |
| Educational attainment, father | 1226 (5.8%) | |||||||
| ≤9 years | 230 (1.1%) | 324 (5.0%) | 66 (8.4%) | 1458 (6.2%) | 218 (7.5%) | 324 (5.0%) | 17 (5.5%) | |
| 10-12 years | 5643 (26.3%) | 885 (29.9%) | 2806 (43.2%) | 388 (49.4%) | 6417 (27.1%) | 838 (28.7%) | 2806 (43.2%) | 118 (38.1%) |
| <2 years tertiary | 7550 (35.2%) | 1060 (4.9%) | 682 (10.5%) | 98 (12.5%) | 8267 (34.9%) | 1019 (34.9%) | 682 (10.5%) | 51 (16.5%) |
| ≥2 years tertiary | 7048 (32.8%) | 778 (3.6%) | 2682 (41.2%) | 233 (29.7%) | 7524 (31.8%) | 842 (28.9%) | 2682 (41.2%) | 123 (39.8%) |
Categorical characteristics are denoted as frequencies (proportions). Continuous characteristics are denoted as median (inter quartile range).
ASD, autism spectrum disorder, ADHD, attention-deficit hyperactivity disorder, NA, data not available; wk, weeks; mths, months.
Early-life antibiotics use and subsequent risk of ADHD in Dutch (NTR) and Swedish (CATSS) twin cohorts
| OR adjusted (95% CI) | ||||
|---|---|---|---|---|
| NTR | Unmatched | 1100/2972 (37.0%) | 7520/21 479 (35.0%) | 1.08 (1.00-1.16) |
| MZ and same sex DZ | 406/1098 (37.0%) | 422/1098 (38.4%) | 0.80 (0.59-1.08) | |
| Same sex DZ | 287/750 (38.3%) | 300/750 (40.0%) | 0.74 (0.52-1.05) | |
| MZ | 119/348 (34.2%) | 122/348 (35.1%) | 0.90 (0.48-1.69) | |
| CATSS | Unmatched | 541/1070 (50.6%) | 2718/6179 (44.0%) | 1.14 (1.00-1.30) |
| MZ and same sex DZ | 207/439 (47.2%) | 194/439 (44.2%) | 1.73 (1.02-2.92) | |
| Same sex DZ | 133/278 (47.8%) | 117/278 (42.1%) | 1.71 (0.98-2.98) | |
| MZ | 74/161 (46.0%) | 77/161 (47.8%) | 0.80 (0.37-1.76) | |
| Pooled result unmatched analyses | 1.10 (1.02-1.17) | |||
| Pooled result MZ | 0.82 (0.62-1.08) | |||
ADHD, attention-deficit hyperactivity disorder; AB, users of any antibiotics; MZ, monozygotic twin pair level; DZ, dizygotic twin pair level; OR, odds ratio; CI, confidence interval.
Adjusted for gender, delivery mode, educational attainment, birthweight, breastfeeding, asthma.
Adjusted for birthweight, asthma.
Adjusted for gender, delivery mode, educational attainment, birthweight, asthma.
p <0.05; **p <0.01; ***p <0.001.
Early-life antibiotics use and subsequent risk of ASD in Dutch (NTR) and Swedish (CATSS) twin cohorts
| OR adjusted (95% CI) | ||||
|---|---|---|---|---|
| NTR | Unmatched | 1131/2976 (38.0%) | 7089/20 876 (34.2%) | 1.14 (1.05-1.23) |
| MZ and same sex DZ | 490/1250 (39,2%) | 503/1250 (40.2%) | 0.88 (0.66-1.17) | |
| Same sex DZ | 314/780 (40.3%) | 312/780 (40.0%) | 0.98 (0.70-1.36) | |
| MZ | 178/470 (37.9%) | 189/470 (40.2%) | 0.66 (0.38-1.16) | |
| CATSS | Unmatched | 170/350 (48.8%) | 3334/7466 (44.7%) | 1.29 (0.96-1.74) |
| MZ and same sex DZ | 44/81 (54.3%) | 43/81 (53.1%) | 1.43 (0.52-3.89) | |
| Same sex DZ | 30/49 (61.2%) | 26/49 (53.1%) | 2.23 (0.65-7.57) | |
| MZ | 14/32 (43.8%) | 15/32 (46.9%) | 0.29 (0.02-4.50) | |
| Pooled result unmatched analyses | 1.15 (1.06-1.25) | |||
| Pooled result MZ | 0.64 (0.37-1.10) | |||
ASD, autism spectrum disorder; AB, users of any antibiotics; MZ, monozygotic twin pair level; DZ, dizygotic twin pair level; OR, odds ratio; CI, confidence interval.
Adjusted for gender, delivery mode, educational attainment, birthweight, breastfeeding, asthma.
Adjusted for birthweight, asthma.
Adjusted for gender, delivery mode, educational attainment, birthweight, asthma.
p <0.05; **p <0.01; ***p <0.001.